
AI technique used to treat metastatic cancer patient: Study
India TV NewsSingaporean researchers have harnessed the power of artificial intelligence to successfully treat a patient with advanced cancer, completely halting disease progression. The novel CURATE.AI platform, developed by the National University of Singapore, halted the progression of advanced cancer by continuously optimising novel drug combination. In a clinical study, a patient suffering with metastatic castration-resistant prostate cancer was given a novel drug combination consisting of investigational drug ZEN-3694 and enzalutamide -- approved drug for prostate cancer. The CURATE.AI platform uses the patient's own clinical data -- such as their drug doses and corresponding changes to tumour sizes or levels of cancer biomarkers in the blood -- to calibrate his or her unique response to treatment. This calibration is then used to create an individualised CURATE.AI profile or map, which identifies the drug doses that enable the best possible treatment outcome at any given point in time.
History of this topic

AI to detect prostate cancer as charity backs technology
The Independent
Artificial intelligence detected prostate cancer when Greg had no symptoms — here's how the technology can save other men's lives
ABC
Cancer drug developed using AI shrinks tumours by a quarter
WiredDiscover Related











































